Entries by chi9iua

Chime Biologics Partners Polpharma Biologics to Advance Global Biosimilar Development

Chime Biologics Partners Polpharma Biologics to Advance Global Biosimilar Development Accelerate Polpharma Biologics biosimilar program from IND to commercial manufacturing Includes a commitment to producing for US FDA BLA submission Expand global market presence through launch in EU and other regions April 16, 2025, Gdańsk, Poland and Shanghai, China – Chime Biologics, a leading global […]

Chime Biologics Supports Mabgeek to Advance MG-K10 into Phase III Trials and Enter the U.S. Market

Chime Biologics Supports Mabgeek to Advance MG-K10 into Phase III Trials and Enter the U.S. Market February 21, 2025, Shanghai – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, today announced its continued collaboration with Mabgeek in advancing MG-K10, a potential Best-in-Class therapy, a novel IL-4Rα-targeting antibody drug for atopic […]

Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization

Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization -Process Performance Qualification (PPQ) validates robust manufacturing standards and is crucial for regulatory compliance -Marks a key step forward for the world’s first once-monthly IL-4Rα-targeting antibody therapeutic for Th2-driven diseases, with a strategic […]